1. Home
  2. AFMD

as 05-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Founded: 2000 Country:
Germany
Germany
Employees: N/A City: N/A
Market Cap: 71.7M IPO Year: 2014
Target Price: $32.00 AVG Volume (30 days): 92.6K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -7.67 EPS Growth: N/A
52 Week Low/High: $2.24 - $9.10 Next Earning Date: 05-28-2024
Revenue: $9,194,444 Revenue Growth: -79.99%
Revenue Growth (this year): -35.26% Revenue Growth (next year): 16.56%

Share on Social Networks: